Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Biomol Struct Dyn ; 41(20): 11017-11043, 2023 12.
Article in English | MEDLINE | ID: mdl-37054526

ABSTRACT

As breast cancer remains leading cause of cancer death globally, it is essential to develop an affordable breast cancer therapy in underdeveloped countries. Drug repurposing offers potential to address gaps in breast cancer treatment. Molecular networking studies were performed for drug repurposing approach by using heterogeneous data. The PPI networks were built to select the target genes from the EGFR overexpression signaling pathway and its associated family members. The selected genes EGFR, ErbB2, ErbB4 and ErbB3 were allowed to interact with 2637 drugs, leads to PDI network construction of 78, 61, 15 and 19 drugs, respectively. As drugs approved for treating non cancer-related diseases or disorders are clinically safe, effective, and affordable, these drugs were given considerable attention. Calcitriol had shown significant binding affinities with all four receptors than standard neratinib. The RMSD, RMSF, and H-bond analysis of protein-ligand complexes from molecular dynamics simulation (100 ns), confirmed the stable binding of calcitriol with ErbB2 and EGFR receptors. In addition, MMGBSA and MMP BSA also affirmed the docking results. These in-silico results were validated with in-vitro cytotoxicity studies in SK-BR-3 and Vero cells. The IC50 value of calcitriol (43.07 mg/ml) was found to be lower than neratinib (61.50 mg/ml) in SK-BR-3 cells. In Vero cells the IC50 value of calcitriol (431.05 mg/ml) was higher than neratinib (404.95 mg/ml). It demonstrates that calcitriol suggestively downregulated the SK-BR-3 cell viability in a dose-dependent manner. These implications revealed calcitriol has shown better cytotoxicity and decreased the proliferation rate of breast cancer cells than neratinib.Communicated by Ramaswamy H. Sarma.


Subject(s)
Breast Neoplasms , Calcitriol , Animals , Chlorocebus aethiops , Humans , Female , Calcitriol/pharmacology , Calcitriol/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Vitamin D/pharmacology , Vitamin D/therapeutic use , Vero Cells , Signal Transduction
2.
Lupus ; 32(4): 560-564, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36731873

ABSTRACT

INTRODUCTION: Patients with SLE (systemic lupus erythematosus) have a higher risk of infection due to dysregulated immune system as well as long-term use of immunosuppressants (IS). This could influence the risk of COVID-19 and its outcome. METHODS: We conducted a longitudinal prospective study across 15 rheumatology centres during the first wave of the pandemic to understand the risk factors contributing to COVID-19 in SLE patients. During the 6 months follow-up, those who tested positive for COVID-19, their clinical course and outcome information were recorded. RESULTS: Through the study period (April-December 2020), 36/1379 lupus patients (2.9%) developed COVID-19. On analysing the COVID-19 positive versus negative cohort during the study period, male gender (adjusted RR 3.72, 95% C.I. 1.85,7.51) and diabetes (adjusted RR 2.94, 95% C.I. 1.28, 6.79) emerged as the strongest risk factors for COVID-19, in the adjusted analysis. There was no significant influence of organ involvement, hydroxychloroquine, glucocorticoid dosage (prednisolone< 7.5 mg or ≥ 7.5 mg/day) or IS on the risk of COVID-19. There was only one death (1/36) among the lupus patients due to COVID-19. CONCLUSION: Traditional risk factors rather than lupus disease process or IS influenced the risk of COVID-19 in our cohort.


Subject(s)
COVID-19 , Lupus Erythematosus, Systemic , Humans , Male , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/drug therapy , Prospective Studies , COVID-19/complications , Longitudinal Studies , Immunosuppressive Agents/adverse effects , Risk Factors
3.
Int J Biol Macromol ; 131: 779-786, 2019 Jun 15.
Article in English | MEDLINE | ID: mdl-30902721

ABSTRACT

Crosslinking of proteins such as collagen for enhanced stability and mechanical properties is an intriguing area in the context of both biomedical and industrial applications. Herein, we have shown the crosslinking of collagen fibers using visible light in a green solvent, ethanol, in the presence of photosensitizers such as methylene blue (Mb) and erythrosine B (Eb). The visible light induced crosslinking increases the shrinkage temperature of collagen fibers from 67 to 100 °C in a concentration dependent manner (1.0 mM Mb/Eb) as revealed by differential scanning calorimetry. Such manifestation was possible only in the presence of ammonium persulphate, a photo-initiator, which has been corroborated through enzymatic degradation, fluorescence and Raman spectroscopic studies. We have also demonstrated that the photoexcited tyrosine moiety of collagen fibers form di-tyrosine during the crosslinking between the peptide chains through steady-state and time-resolved fluorescence measurements. The results suggest a new and efficient photocrosslinking technique to stabilize proteins for diverse applications.


Subject(s)
Collagen/chemistry , Light , Photochemical Processes , Collagen/ultrastructure , Protein Aggregates , Protein Stability , Proteolysis , Solvents , Spectrum Analysis , Thermodynamics
SELECTION OF CITATIONS
SEARCH DETAIL
...